MP38-01 BIOACTIVE FIBROUS MEMBRANE CONTAINING ENDOGENOUS NERVE GROWTH FACTOR PROMOTES CELLULAR AND FUNCTIONAL RECUPERATION OF IMPAIRED CAVERNOUS NERVE: AN <i>IN VIVO</i> ANIMAL STUDY

Introduction And Objective&#13;\nProstate cancer is a frequent disease and the radical prostatectomy one of the most used treatment when the cancer is localized. This procedure commonly causes erectile dysfunction (ED) by injure the cavernous nerve (CN) during the surgery.With this research we investigate the ability of a bioactive fibrous membrane (FM) to regenerate the damaged CN in a rat model of CN injury.&#13;\n&#13;\n&#13;\n&#13;\nMethods&#13;\nMale Spragueâ Dawley (SD) rats were distributed by 4 experimental groups: sham (only a lower midline abdominal incision), negative control (lower midline abdominal incision with pelvic dissection and CN crush but no FM implantation), electrospun fibrous membrane [eFM] (with CN crush and FM implantation) and electrospun fibrous membrane biofunctionalized with NGF from rat urine [eFM-uNGF] (with CN crush). Function was evaluated five weeks later after an injection of apomorphine by glans observation (visual scoring) and intracavernous pressure (ICP) measurements. Neurogenic genes expression and Histological and Immunohistochemical analysis of CN and cavernous tissue was performed.&#13;\n&#13;\n&#13;\n&#13;\nResults&#13;\nin this model of bilateral CN crush the treatment with implanted bioactive fibrous membrane induces CN regeneration and restoration of erectile function (p &lt;0.001) (figure), showing a significant increased number of smooth muscle cells and nNOS and eNOS contents. Additionally, the bioactive fibrous membrane promotes a CN protective effect and increase the nerve regeneration capacity by increasing the number of myelinated axons and nNOS-positive cells, recovering from the CN fibrosis observed in rats not treated.&#13;\n&#13;\n&#13;\n&#13;\nConclusions&#13;\nThis personalized regenerative strategy could help better recovery of erectile function after CN injuries, and it may constitute an effective novel option to prostate cancer patients suffering from ED after being subject to radical prostatectomy.